There is no company description available for NextCure Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone240-399-4900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
NextCure (NASDAQ:NXTC) Frequently Asked Questions
What is NextCure's stock symbol?
NextCure trades on the NASDAQ under the ticker symbol "NXTC."
How were NextCure's earnings last quarter?
NextCure Inc (NASDAQ:NXTC) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.61) EPS for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.15. The business earned $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. View NextCure's Earnings History.
When is NextCure's next earnings date?
What price target have analysts set for NXTC?
3 brokerages have issued 1-year price targets for NextCure's stock. Their forecasts range from $33.00 to $54.00. On average, they expect NextCure's share price to reach $43.67 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price. View Analyst Price Targets for NextCure.
What is the consensus analysts' recommendation for NextCure?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.
Has NextCure been receiving favorable news coverage?
News headlines about NXTC stock have trended negative on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. NextCure earned a news impact score of -2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for NextCure.
Are investors shorting NextCure?
NextCure saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 482,000 shares, an increase of 88.1% from the August 30th total of 256,200 shares. Based on an average trading volume of 80,500 shares, the short-interest ratio is presently 6.0 days. Approximately 3.9% of the shares of the company are sold short. View NextCure's Current Options Chain.
Who are some of NextCure's key competitors?
Some companies that are related to NextCure include Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), BridgeBio Pharma (BBIO), Ra Pharmaceuticals (RARX), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Cambrex (CBM), Xencor (XNCR), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Portola Pharmaceuticals (PTLA) and Zogenix (ZGNX).
What other stocks do shareholders of NextCure own?
When did NextCure IPO?
(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.
When does the company's lock-up period expire?
NextCure's lock-up period expires on Tuesday, November 5th. NextCure had issued 5,000,000 shares in its public offering on May 9th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Who are NextCure's major shareholders?
NextCure's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Strs Ohio (0.03%). Company insiders that own NextCure stock include Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.
Which institutional investors are buying NextCure stock?
NXTC stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought NextCure stock in the last two years include Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.
How do I buy shares of NextCure?
Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NextCure's stock price today?
One share of NXTC stock can currently be purchased for approximately $27.23.
How big of a company is NextCure?
What is NextCure's official website?
How can I contact NextCure?
NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]
MarketBeat Community Rating for NextCure (NASDAQ NXTC)
MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote "Outperform" if you believe NXTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
